This product is a second-generation sulfonylurea oral hypoglycemic drug. Its main mechanism of hypoglycemic effect is to stimulate pancreatic beta cells to secrete insulin and partially increase the sensitivity of surrounding tissues to insulin. This product binds to and dissociates from insulin receptors faster than glibenclamide and is less likely to cause severe hypoglycemia.

Selenium and vitamin E work together in the body to protect cell membranes and prevent the oxidation of unsaturated fatty acids. Trace amounts of selenium have anti-cancer and liver-protecting effects.

1. Increase myocardial blood flow and have a significant protective effect on myocardial ischemia. 2. Lower blood pressure and protect target organs. 3. Lower serum cholesterol and triglycerides. 4. Improve the body's immune function and delay aging.

Calcium blockers (also known as slow channel blockers or calcium antagonists) block the entry of calcium ions across the membrane into myocardial and vascular smooth muscle cells.

This product is a hypoglycemic drug that can reduce fasting and postprandial hyperglycemia in patients with type 2 diabetes. Its hypoglycemic mechanism is: 1. Increase the sensitivity of peripheral tissues to insulin and increase insulin-mediated glucose utilization; 2. Increase the utilization of glucose by non-insulin-dependent tissues, such as the brain, blood cells, renal medulla, intestines, skin, etc.; 3. Inhibit hepatic gluconeogenesis and reduce hepatic glucose output; 4. Inhibit intestinal wall cells from taking up glucose. Unlike insulin, this product does not promote fat synthesis and has no obvious hypoglycemic effect on normal people. It generally does not cause hypoglycemia when used alone for type 2 diabetes.